Abexxa Biologics is a biopharmaceutical firm employing a fresh strategy in the realms of immuno-oncology and oncology to pioneer the next phase of precision medicine. Abexxa's primary focus lies in crafting innovative therapeutics centered on its recently discovered category of intracellular antigens (unconventional HLA-peptide complexes) found on cancerous cells. These unconventional HLA-peptide complexes offer opportunities to previously untapped targets and have demonstrated their influence in regulating innate and adaptive immune responses.